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Abstract
The  MuvB  transcriptional  regulatory  complex,  which  controls  cell-cycle
dependent gene expression, cooperates with B-Myb to activate genes required for
the G2 and M phases of the cell cycle. We have identified the domain in B-Myb that
is essential for the assembly of the Myb-MuvB (MMB) complex. We determined a
crystal  structure  that  reveals  how  this  B-Myb  domain  binds  MuvB  through  the
adaptor  protein  LIN52  and scaffold  protein  LIN9.  The  structure  and biochemical
analysis provides an understanding of how oncogenic B-Myb is recruited to regulate
genes  required  for  cell-cycle  progression,  and  the  MMB  interface  presents  a
potential therapeutic target to inhibit cancer cell proliferation.
 
Significance Statement
Myb family transcription factors are potent activators of cell  proliferation and
drivers of human cancer. B-Myb, the most ancient and conserved family member,
induces transcription of mitotic genes. The MuvB complex, thought to be the master
regulator of cell-cycle dependent gene expression, is required for directing B-Myb to
the proper promoters. We present the first structural description of MuvB and how it
recruits B-Myb. We identified a direct association between the B-Myb C-terminus
and the MuvB components LIN9 and LIN52, and we determined the crystal structure
of this subcomplex. Our data define LIN52 as a central transcription factor-binding
hub in MuvB and reveal a Myb-MuvB interface that could be targeted with chemical
inhibitors.
/body
Introduction
There are three paralogous MYB genes in vertebrates that code for transcription
factors:  MYB  (c-Myb),  MYBL1  (A-Myb) and MYBL2  (B-Myb).  MYB and  MYBL1 are
involved  in  recurrent  chromosomal  translocations  in  human  leukemia,  adenoid
cystic carcinoma, and pediatric glioma (1-3). Increased levels of MYBL2 expression
have been observed in breast cancer and are a predictor of poor prognosis  (4).
Consistent with an essential role in proliferation, B-Myb is present in all mitotically
cycling cells  (5), and  MYBL2 germline knockout mice display an early embryonic
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lethal  phenotype  (6).  In contrast,  c-Myb and A-Myb appear to be tissue and cell
type-specific (7, 8). 
 The Myb protein architecture contains a DNA-binding domain, a transactivation
domain, and a negative regulatory domain (NRD) (Fig. 1a). The C-terminus has been
referred to as the NRD because deletion of this region in all  three Myb proteins
promotes the activation of Myb-regulated genes in cell-based reporter assays  (9-
12).  In  human  leukemia,  adenoid  cystic  carcinoma,  and  pediatric  glioma,
chromosomal  rearrangements  create  fusion  proteins  with  truncations  of  the  C-
terminus of c-Myb or A-Myb that remove the NRD and result in increased Myb target
gene expression (1-3). The NRD is also absent in the transforming avian oncogene
V-MYB, and deletion of the C-terminus of c-Myb, in a fashion similar to v-Myb, is
sufficient for oncogenic activation (3, 10). 
Other  evidence  suggests  that  the  C-terminus  of  B-Myb  primarily  plays  an
activating  role.  Unlike  the  other  family  members,  C-terminal  truncation  of  the
MYBL2 gene in human cancers has not been reported. The C-terminus of human B-
Myb has been observed to enhance transcriptional activation when fused to c-Myb
(13). Moreover, the C-terminus of Drosophila Myb (dMyb), an ortholog of B-Myb, is
essential for association with the MuvB complex and mutations in this region abolish
its activity  (14, 15). These results suggest that part of the NRD may have some
activating  function  related  to  Myb-MuvB  (MMB)  complex  assembly,  but  further
structure-function analysis of this domain is needed. 
The MuvB complex cooperates with B-Myb during S-phase of the cell cycle to
activate mitotic genes (16, 17). Cells require the MuvB complex and B-Myb or dMyb
to  undergo  mitosis,  as  disruption  of  the  Myb-MuvB  (MMB)  complex  results  in
abnormal  spindle  assembly  (14,  15,  17,  18).  Essential  G2/M  cell-cycle  genes
activated by MMB contain a cell-cycle homology region (CHR) DNA element in their
promoters (16, 17, 19, 20). The MuvB complex is assembled from five core proteins
RBAP48,  LIN54,  LIN52,  LIN37,  and  LIN9  (16,  21-24).  This  MuvB  core  binds  the
retinoblastoma protein paralog p130 and the transcription factor E2F4/5-DP1/2 to
form the DREAM complex, which represses cell-cycle genes in quiescence and in G1
phase (16, 23, 24). In S phase, MuvB dissociates from p130 and B-Myb binds to form
MMB (17, 20, 25). RBAP48 is a histone binding protein, and LIN54 directly binds the
CHR DNA element  in  cell-cycle  gene  promoters  (26,  27).  LIN52  mediates  MuvB
association  with  p130  to  form  DREAM  (25,  28).  LIN9  and  LIN37  have  poorly
3
characterized  biochemical  functions  but  are  required  for  MuvB-regulated  gene
expression (18, 29). 
These studies suggest that B-Myb function is linked to the MuvB complex and
the CHR element, from which it can activate genes required for mitosis. Here we
present the structure of the C-terminus of B-Myb, and define its role as a MuvB-
binding domain (MBD). We find that B-Myb assembles with the MuvB complex by
accessing domains of LIN52 and LIN9. Our findings describe a conserved role for
this MMB interface in cell-cycle progression and highlight a unique target for cancer
therapeutics.
Results
Determinants for assembly of the Myb-MuvB complex
We first  identified  the B-Myb domain requirements  for  human MMB complex
assembly. Using a co-immunoprecipitation assay (co-IP) in T98G cells, we found that
the  C-terminus  of  B-Myb  (residues  375-700)  is  necessary  and  sufficient  for
association with LIN37 and other MuvB components (Fig. 1b), which was similarly
observed in Drosophila dMyb (14). Mutating the conserved residues Q674 and M677
was  sufficient  to  disrupt  MMB  complex  formation.  Based  on  these  data,  the
sequence conservation in the Myb C-terminus (Fig. 1a and Fig. S1), and our previous
observation that B-Myb residues 654-700 are sufficient to bind recombinant MuvB
(25), we conclude that the C-terminus of B-Myb contains a MuvB-binding domain
(MBD).  A  small  fragment  of  the  B-Myb  C-terminus  (Fig.  1b,  residues  657-688,
hereafter  called  MBD)  did  not  efficiently  express  in  T98G  cells,  so  we  further
explored its association with MuvB using recombinant proteins.
We reconstituted a minimal human MuvB complex in vitro by co-expressing five
proteins in Sf9 cells (25). This recombinant MuvB forms a stable complex with full-
length  recombinant  B-Myb that  co-elutes  in  size-exclusion  chromatography  (Fig.
2a). To identify the critical MuvB domains for B-Myb association, we implemented a
quantitative  fluorescence  polarization  (FP)  assay  using  a  rhodamine-labeled
synthetic MBD peptide. We found that the minimal MuvB complex binds B-Myb MBD
with  high  affinity  (Kd =  1.2  ±  0.1  nM)  (Fig.  2b).  LIN52  is  necessary  for  MMB
reconstitution  (25),  but LIN52 alone bound MBD 150-fold weaker than the MuvB
complex, suggesting that additional MuvB proteins contribute to MBD association
(Fig. 2b and Fig. S2). LIN9 is also required for MMB assembly in cells  (16, 20, 30).
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Although we could not express soluble recombinant LIN9 alone, we could purify a
sub-complex including conserved regions in LIN9 (residues 349-466, LIN9349-466) and
the C-terminus of LIN52 (residues 52-116, LIN5252-116)  (Fig. S3). This sub-complex
binds B-Myb MBD with similar affinity to the entire minimal MuvB (Fig. 1d and Fig.
S2), suggesting that LIN9 and LIN52 form the binding interface that recruits B-Myb
to the MuvB complex. 
 We assayed whether the A-Myb and c-Myb MBD sequences, which show some
conservation with B-Myb (Fig. 1a and Fig. S1), could bind the LIN9349-466-LIN5252-116
sub-complex  using  isothermal  titration  calorimetry  (ITC)  (Fig.  2c).  The  ITC
measurement shows tight  association of  B-Myb MBD,  albeit  with  weaker  affinity
than  in  the  FP  assay.  A-Myb  MBD  associates  with  LIN9-LIN52  but  with  50-fold
weaker affinity than B-Myb, and c-Myb MBD did not produce detectable binding (Fig.
2c).  These  results  explain  the  previous  observations  that  MuvB  does  not  co-
precipitate A-Myb or c-Myb as strongly as B-Myb from cell extracts (16, 20). The
MBD sequence from Drosophila  (dMyb), which is representative of the single Myb
found in invertebrates (Fig. 1a and Fig. S1), binds human LIN9-LIN52 with 13-fold
weaker affinity than B-Myb (Fig. 2c). 
Crystal structure reveals the Myb-MuvB interface
 To  resolve  the  molecular  details  of  the  MMB complex,  we  used anomalous
diffraction approaches to solve a 2.3 Å crystal structure of B-Myb MBD bound to the
LIN9349-466-LIN5252-116  sub-complex  (Fig.  3,  Table  S1,  and  Fig.  S4).  The LIN9-LIN52
heterodimer  forms  a  three-stranded  antiparallel  coiled-coil  as  the  core  of  the
structure (Fig. 3a). LIN9 contributes two helices (1 and 2), which run antiparallel
and are connected through a short linker. The third helix is from LIN52 (LIN52 2)
and is parallel with LIN9 1. LIN52 contains a second shorter helix (1) that covers a
face of the coiled-coil near the N-termini of LIN9 1 and LIN52 2. 
The B-Myb MBD forms two short helices that bind the coiled-coil surface formed
by LIN9 2 and LIN52 2 (Fig. 3a). The first MBD helix (MBD 1, residues 663-668) is
comprised of a single turn with its axis pointing toward the center of the coiled-coil.
B-Myb residues W663, V666, and A667, and C668, which are conserved in many B-
Myb orthologs (Fig. S1), make a number of van der Waals contacts with both LIN52
(A91, Y92, L96 and G95) and LIN9 (L418, N419, and L422) (Fig. 4a).  An alanine
mutation of LIN52 at Y92, which inserts between B-Myb W663 and V666, reduces
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affinity  of  B-Myb  60-fold  (Fig.  4b).  The  sidechain  of  K372  in  LIN9  1,  which  is
conserved in LIN9 orthologs (Fig. 3b), forms a hydrogen bond with the backbone
carbonyl  of  A667  in  B-Myb.  The  positive  lysine  likely  stabilizes  the  negative  C-
terminal dipole of the MBD 1 helix (Fig. 4a), and a LIN9 K372A mutation reduces B-
Myb MBD affinity 6-fold (Fig. 4b). The close approach of MBD 1 to the core of the
coiled-coil is possible because of the lack of a sidechain at G95 in LIN52. G95 is
conserved in LIN52 (Fig. 3b), and a G95S mutation reduces the affinity of the MBD
50-fold (Fig. 4b). 
The second B-Myb MBD helix (2) binds the N-terminus of LIN9  2 and the C-
terminus of LIN52 2 (Figs. 3a, 4a, and S5). This interface is primarily stabilized by
interactions involving B-Myb residues Q674, M677, A681, and R682 (Fig. 4A and S5).
M677 docks into a hydrophobic pocket formed by M102, G105 and K106 in LIN52
and Y404 and V408 in LIN9, while A681 contacts L111 in LIN52 and A405, V408, and
L409 in LIN9. R682 in MBD  2 makes a salt bridge with E412 in LIN9. We tested
substitutions of several of these interacting residues in LIN9 and LIN52 using the ITC
assay, and in each case found weaker MBD association (Fig. 4b). We also found that
full-length LIN9 containing a V408A/L409A mutation has weaker affinity for B-Myb,
but not LIN37, in a co-IP assay in HeLa cells (Fig. 4c). While we cannot rule out the
possibility of additional interactions between the full-length proteins in cells, this co-
IP result is consistent with the weaker affinity measured using the protein fragments
in the FP assay.
Q674 in the B-Myb MBD is also buried at the interface with the LIN9-LIN52 dimer.
The glutamine sidechain makes hydrogen bonds with the sidechains of E98 in LIN52
and N415 in LIN9 (Fig. 4a and S5). LIN9 N415 also hydrogen bonds and positions
LIN9 K372 for stabilizing MBD  1, while LIN52 E98 also hydrogen bonds with the
backbone amide of G669 in B-Myb. Together these four buried polar residues (B-
Myb Q674, LIN9 K372 and N415, and LIN52 E98) form a hydrogen bond network
that brings together all five helices in the coiled-coil and B-Myb (Fig. 4a). A LIN52
E98A mutation and LIN9 N415A mutation reduce the MBD affinity 110-fold and 55-
fold respectively, supporting the importance of these interactions (Fig. 4b). 
Conservation of the Myb-MuvB association
The structure of the MBD interface accounts for mutations in dMyb that were
deleterious to its function in Drosophila (Fig. S6) (14, 15). D673A/Q674A (human B-
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Myb numbering)  and W663A mutants  failed  to  rescue dMyb-deficient  cells  from
arresting in G2/M, failed to bind to MuvB, and failed to activate expression of a Polo
transgene  in vivo  (14).   Notably, we found that alanine substitutions at M621 or
Q618 in dMyb (equivalent to M677 and Q674 in B-Myb) result in loss of association
in the ITC assay (Fig. S2). These results, the conservation between B-Myb and dMyb,
and the observation that B-Myb can compensate for dMyb  in vivo  (31) together
establish  the  functional  importance  of  the  interface  observed  in  the  crystal
structure. 
The molecular details revealed by the structure of the MBD-LIN9-LIN52 complex
also explain the preference of B-Myb over other Myb family members for MuvB (Fig.
2c) (20). A large hydrophobic residue is conserved at the M677 position in B-Myb in
vertebrates  and  Myb  in  simpler  metazoans,  whereas  a  serine  is  substituted  in
human c-Myb (Fig. 1a and S1). c-Myb, which does not bind LIN9-LIN52 (Fig. 2c), also
lacks critical interacting residues in the MBD 1 helix (V666 and A667 in B-Myb). A-
Myb also contains differences in the MBD  1 helix, which may explain its weaker
affinity for MuvB. dMyb does not contain R682 in 1, which makes the salt bridge
with LIN9 E412, and it also binds human LIN9-LIN52 with weaker affinity than B-
Myb. 
The LIN9 and LIN52 residues that are involved in B-Myb binding are conserved
among a wide range of metazoans, including C. elegans, which does not appear to
possess  an  animal-specific  Myb  homolog  (Fig.  3b).  The  conservation  of  these
regions of LIN9 and LIN52 in C. elegans suggests the possibility that this site has an
additional function such as recruitment of a another protein.  The Drosophila tMAC
complex contains MuvB-like proteins that are specific to the testis (32, 33). The LIN9
paralog Aly (Always early), and the LIN52 paralog Wuc (Wake-up-call) have residue
substitutions specifically at regions where B-Myb interacts in our crystal structure
(Fig. 3b). We found using the FP assay that several of these substitutions (G95S,
G105S,  and  A405S)  weaken  B-Myb  affinity  (Fig.  4b),  consistent  with  previous
observations that tMAC does not bind and functions independently of dMyb (32). 
Discussion
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We provide here the first evidence of a direct association between B-Myb, LIN9, and
LIN52 via a ternary sub-complex in MMB. The LIN52 protein also mediates assembly
of the repressive DREAM complex during quiescence and G1 when phosphorylated at
serine 28 by DYRK1A (25, 28). These findings highlight the important role of LIN52 as
an adaptor  protein that  binds either p130 (DREAM) or B-Myb (MMB) to form the
proper complex for regulating gene expression at the right time in the cell cycle (Fig.
5). The LIN52 domain that binds B-Myb in our crystal structure does not overlap with
the sequence that binds p130. This observation is consistent with our finding that B-
Myb and p130 do not directly compete for MuvB association (25) and the observation
that dMyb and fly p130 orthologs co-purify in the same complex (22). We propose
that the interactions between p130 and B-Myb with LIN52 are mutually exclusive in
human cells because of the timing of p130 phosphorylation and B-Myb expression.
Pocket protein-E2F complexes, including DREAM, have been found to repress the
MYBL2 gene until  cell-cycle  entry  (34,  35),  and DREAM dissociation  through Cdk
phosphorylation of p130 occurs as B-Myb levels increase (20, 25). 
Previous studies implicate both B-Myb/dMyb and LIN9 as essential for cell-cycle
gene  activation  and  progression  through  mitosis  (6,  16-18,  36,  37).  Our  data
suggest that a critical activating function of LIN9 is the recruitment of B-Myb to CHR
promoters  via  the  MuvB  complex.  Similarly,  the  data  suggest  that  the  MBD  is
essential for B-Myb-mediated gene activation as the site of MuvB association  (14,
30).  Interestingly,  the C-terminus of  Myb proteins,  which includes the MBD, was
previously considered to be part of a negative regulatory domain  (9-12). The fact
that oncogenic C-terminal truncations are exclusive to c-Myb and A-Myb, neither of
which bind MuvB strongly, suggests that the C-terminal domain of those paralogs
regulates  transcription  using additional  mechanisms that  are  MuvB-independent.
However, it remains possible that these truncations also disrupt binding to the MuvB
core that has yet to be detected.
The  three  MYB genes  in  mammals  display  distinct  phenotypes  in  knockout
studies (6-8), suggesting distinct functions. Phylogenetic analysis indicates that B-
Myb  is  the  most  ancient  vertebrate  Myb family  member,  and  only  B-Myb  can
functionally complement the sole Myb in Drosophila (31). We found here that dMyb
binds LIN9-LIN52 (Fig. 2c) with sub-micromolar affinity and that many invertebrate
Myb proteins contain the critical  residues in the B-Myb MBD that contact  MuvB.
Consistent with these observations, expression of B-Myb but neither c-Myb nor A-
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Myb can partially rescue a Drosophila MYB null mutant (31). Together these results
support the idea that the cell-cycle role of B-Myb-MuvB association is among the
most  conserved  functions  of  Myb  but  was  lost  in  the  more  recently  evolved
vertebrate paralogs.
The LIN9 and LIN52 helical  bundle  could  serve as a therapeutic  target  in
cancer  cells  that  have  high-levels  of  B-Myb  expression.  In  particular,  the
hydrophobic pocket in which M677 docks appears as a potential site that could bind
inhibitors (Figure S5). Decreased levels of either the MuvB complex protein LIN9 or
B-Myb were effective in  reducing cancer  proliferation and tumor  mass  (38,  39).
Targeting this interface would disrupt the activator MMB complex and potentially
restore the DREAM complex to promote quiescence and tumor dormancy (16, 28).
The structure of the Myb-LIN9-LIN52 interface presented here may benefit future
efforts to design cell-cycle inhibitors that target the MMB complex.
Materials and Methods
Protein expression and peptides
Human B-Myb (residues 275-375) was expressed and purified from E. coli  cells
as a GST fusion protein. Untagged human LIN9 (349-466) was co-expressed with
human  GST-LIN52  (52-116).  Cells  were  induced  with  0.2  mM  IPTG  and  grown
overnight at 18°C. Proteins were first purified with glutathione affinity and anion
exchange chromatography. The GST tag was cleaved with TEV protease, and the
protein was passed over affinity resin again to remove free GST and concentrated. 
LIN52,  LIN37,  RBBP48,  LIN9  (94-542),  LIN54  (589-749)  and  B-Myb  were
expressed  in  Sf9  cells  (Expression  Systems,  Davis  CA)  using  baculoviruses  and
purified  as  described  above.  The  B-Myb657-688,  SeMet  B-Myb657-688 and  TAMRA-B-
Myb657-688 peptides were synthesized by BioPeptide LLC., and all other peptides were
synthesized by GenScript Inc. 
Crystallization,  data  collection,  structure  determination,  and  model
refinement
LIN52-LIN9  sub-complex  was  prepared  for  crystallization  by  elution  from  a
Superdex 75 column in a buffer containing 10 mM Tris, 100 mM NaCl, and 1 mM
DTT (pH 8.0). B-Myb657-688 was added in 3-fold molar excess to 10 mg/mL LIN52-LIN9.
Crystals were grown by sitting-drop vapor diffusion at 22°C in 100 mM citric acid
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and 5% PEG 6000 (pH 5). Crystals were frozen in 100 mM HEPES, 10% PEG 400,
20% glycerol  and 1M NH4SO4 (pH 7).  Selenomethionine derivative crystals  were
grown using SeMet B-Myb657-688 in 100 mM citric acid and 5% PEG 6000 (pH 5) under
Al’s  oil  at  22°C.  Streak  seeding using  native  complex  crystals  was  required for
derivative crystal growth.
Data  were  collected  at  the  Advanced  Photon  Source,  Argonne  National
Laboratory at beamline 23-IDB and the Advanced Light Source, Laurence Berkeley
National Laboratory at beamline 8.3.1 and 5.0.1. Diffraction spots were integrated
using  MOSFLM,  and  data  were  merged  and  scaled  using  Scala.  Experimental
phasing was solved using Phenix autosol. The model was built with Coot, and the
model was refined with Phenix. The complex crystalized with two molecules in the
asymmetric  unit  (Fig.  S4).  The  structural  model  and  structure  factors  were
deposited into the Protein Data Bank under accession code 6C48.
Calorimetry:
Isothermal titration calorimetry was performed with a Micro Cal VP-ITC system.
Peptides and proteins were dialyzed overnight and titrated into a buffer containing
20 mM Tris,  150 mM NaCl,  and 1 mM BME, pH 8.0 at  20°C. To circumvent the
difficulty  in  accurately  determining  peptide  concentration,  data  fitting  was
performed by fixing the complex stoichiometry to an equimolar ratio. The molecular
stoichiometry  observed  in  the  crystal  structure  supports  this  assumption  in  the
analysis.
Fluorescence Polarization Assay:
TAMRA-labeled B-Myb657-688 was mixed at 20 nM with MuvB, LIN52, or LIN9-LIN52
in a buffer containing 50 mM Tris, 150 mM NaCl, 1 mM DTT, 0.1% Tween, pH 8.0. 20
μL  of  the  reaction  was  used for  the  measurement  in  a  384-well  plate  well.  FP
measurements were made in triplicate using a Perkin-Elmer EnVision plate reader. 
Co-immunoprecipitation assays
Human  T98G  cells  (ATCC  #CRL  1690)  were  transiently  transfected  with
pcDNA3.1 vectors encoding a GFP-only control, or GFP-tagged wild-type or mutant
B-Myb alleles. HeLa cells (ATCC CCL-2™) were infected with retroviruses produced
using  pMSCV-Puro  vectors  encoding  HA-tagged  wild-type  or  mutant  B-Myb,  and
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selected using 1 μg/ml of puromycin. Cell  extracts were prepared 36 hours later
using EBC lysis buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 0.5% NP-40, protease
and  phosphatase  inhibitor  cocktails)  and  immunoprecipitated  using  anti-LIN37
antibody as previously described (16, 28). Lysates were subjected to Western blot
analysis using mouse antibodies to GFP (Santa Cruz Biotech B-2, sc-9996) and p130
(BD Biosciences) as well as rabbit antibodies against LIN9, LIN37, and LIN52  (16,
28). All antibodies were used at 1:1,000 dilution. 
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Figure Captions
Fig.  1.  The  B-Myb  C-terminal  domain  is  necessary  and  sufficient  for  MuvB
association. a, Domain architecture of Myb proteins (sequence numbering for human B-
Myb), including a DNA-binding domain (DBD), transactivation domain (TAD), and a negative
regulatory domain (NRD). The MuvB binding domain (MBD, residues 657-688) investigated
here is within the NRD and has the aligned sequence. The secondary structure and amino
acids that interact with MuvB (asterisks) are determined from the crystal structure in this
study.  Amino acids that  are identical  in vertebrate B-Myb orthologs and Drosophila  Myb
(dMyb) are highlighted green, with changes at these positions in A-Myb and c-Myb shown in
red and blue (Fig. S1). b, T98G cells were transfected with plasmids encoding the indicated
GFP-B-Myb fusion protein. Vector expresses GFP only. Lysates were immunoprecipitated with
an anti-LIN37 antibody, and Western blots performed to assay the protein of interest. The
asterisk marks immunoglobulin bands from the primary antibody.
Fig. 2. The Myb MuvB binding domain (MBD) directly binds LIN9 and LIN52. a,
Superdex 200 chromatograms and a Coomassie-stained SDS-PAGE gel showing proteins in
the peak fractions.  b, FP measurements of the affinity of the indicted proteins. Data are
shown  for  the  labeled  MBD  peptide  titrated  with  MuvB.  c, ITC  binding  measurements
between LIN9349-466-LIN5252-116 and an MBD peptide from each indicated Myb protein (Fig. 1a).
Additional raw data for FP and ITC measurements are shown in Fig. S2.
Fig.  3.  Crystal  structure  of  the  B-Myb  MBD bound  to  the LIN9349-466-LIN5252-116
heterodimer.  a, Overall  structure.  B-Myb  (green)  binds  the  coiled-coil  formed  by  LIN9
(cyan)  and  LIN52  (yellow).  b,  Sequence  alignments  of  LIN9  and  LIN52  with  secondary
structure, conservation of primary sequence identity (colored boxes), and MBD-contacting
residues (asterisks) indicated. Dashed lines are above sequences that were not included in
the model due to a lack of electron density (LIN9 residues 432-466 were also not included).
Substitutions in the tMAC paralogs at conserved positions in LIN9 and LIN52 are shaded
orange.  Sequences  are  from H.  sapien,  G.  gallus,  D.  melanogaster,  C.  elegans,  and  N.
vectensis.
Fig.  4.  Interactions  stabilizing  the  MBD  interface  with  LIN9-LIN52.  a, View  of
interface  in  crystal  structure.  b, FP measurements  of  B-Myb MBD binding  affinities  with
LIN9349-466-LIN5252-116 containing the indicated mutations. Raw data are shown in Fig. S2.  c,
HeLa cells were transfected with plasmids encoding GFP-B-Myb and Myc-LIN9 fusion proteins
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as indicated. LIN9 Mut contains a V408A/L409A mutation. Lysates were immunoprecipitated
with an anti-Myc antibody, and Western blots performed to assay the protein of interest.
GAPDH is a loading control. 
Fig. 5. LIN52 is an adaptor protein that facilitates DREAM and MMB assembly.
(Top) Domain architecture of LIN52. S28 phosphorylation stimulates association of the LIN52
N-terminus  with  p130.  The  helices  toward  the  C-terminus  of  LIN52  mediate  B-Myb
association. LIN52 recruits p130-E2F4-DP to form DREAM during G0/G1 (bottom left) and B-
Myb to form MMB in S/G2 phase (bottom right), although the interactions are not mutually
exclusive. The promoter elements that bind E2F4-DP (CDE) and MuvB (CHR) are shown.
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